Affimed sets IPO terms, raises series E
Cancer immunotherapy company Affimed Therapeutics AG (Heidelberg, Germany) set the terms for a planned IPO on NASDAQ and also said it closed a EUR 11.7 million ($15.4 million) series E round. The company plans to sell 6.3 million shares at $11-$13 in the IPO. At the $12 midpoint, Affimed would raise $75 million and be valued at $266.8 million. Affimed investors also have said they may buy up to $24 million in shares in the offering Jefferies; Leerink Partners; BMO Capital; and Trout Capital are underwriters.
The E round came from Affimed's existing investors, including Aeris Capital; BioMedInvest; LSP-Life Sciences Partners; Novo Nordisk A/S (CSE:NVO; NYSE:NVO); and OrbiMed. Additionally, Affimed secured a EUR 10.5 million ($13.8 million) loan from Perceptive Advisors. ...